Alopecia

The trial is one of 2 phase 3 studies of upadacitinib in patients with severe alopecia areata.

Janus kinase inhibitors can be paired with corticosteroids or used as monotherapy in the treatment of alopecia areata.

The research showed that certain females—but not males—were at a higher risk of anxiety and depression.

Investigators found that Janus kinase inhibitors were effective in a dose-dependent manner.

Racial and ethnic disparities are found among Asian individuals as they experience the highest lifetime incidence of alopecia areata, and Black individuals face a disproportionately higher risk of anxiety disorders associated with the condition.

The most-read alopecia articles include topics on Janus kinase inhibitors, new therapeutic strategies, health-related quality of life measurements, potential links to the COVID-19 vaccine, and disease pathogenesis.

Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, particularly in those with moderate to severe hair loss.

Patients with treatment-resistant central centrifugal cicatricial alopecia saw improvement in symptoms and gene expression, suggesting the potential of metformin as a new treatment option.

Low-dose oral minoxidil has been agreed upon by an international expert panel as an effective treatment for various hair loss conditions, such as alopecia, with guidelines provided for safe and effective use.

New and in-the-pipeline Janus kinase (JAK) inhibitors have the potential to make huge differences in the lives of patients with this psychologically distressing autoimmune disease.

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, explored the intricate management of alopecia areata, often in tandem with other autoimmune conditions while emphasizing the significance of innovative medications and diagnostic tools, such as dermoscopy, in enhancing patient outcomes.

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, highlighted recent breakthroughs in treating alopecia areata, focusing on the effectiveness of Janus kinase inhibitors and the ongoing challenges related to insurance coverage and patient access.

Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.

Alopecia areata is more prevalent in Hispanic, Asian/Pacific Islander, and Black children than in non-Hispanic White children, with some Asian subgroups having a higher risk compared with those of Chinese ethnicity.

Alopecia areata and asthma are strongly linked, particularly through the inflammatory protein IL-33, suggesting a shared biological pathway and potential for targeted treatments like dupilumab.

Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.

Alopecia areata is linked to specific trace elements, serum metabolites, and inflammatory factors, according to a genetic analysis, suggesting potential new treatment and prevention strategies.

However, an analysis suggested that androgenetic alopecia is not caused by hypothyroidism.

Arash Mostaghimi, MD, MPA, MPH, director of the inpatient dermatology consult service at Brigham & Women's Hospital, discusses the utility of deuruxolitinib for treating moderate to severe alopecia areata (AA).

Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women's Hospital, draws attention to the challenges in identifying specific treatment targets in alopecia areata and the development of effective outcome measures for clinical trials.

The impact alopecia areata (AA) has on patients' health-related quality of life (HRQOL) may not be accurately measured with EQ-5D-5L, suggesting the need for alternative assessments.

Kristen Whitney, DO, FAAD, determines systemic treatment options for severe alopecia areata based on the patient’s medical history, past treatments tried, potential adverse events, in addition to the weighing risk vs benefit of the therapy and the cost for the patient.

Researchers examined the impact of baricitinib withdrawal and retreatment on hair regrowth in patients with severe alopecia areata.

Patients with alopecia areata have a significantly increased risk of developing psychiatric and autoimmune diseases both before and after diagnosis, highlighting the importance of comprehensive care for these individuals.

A bibliometric analysis reveals a significant increase in research on alopecia areata treatment over the past 2 decades, with a focus on identifying effective therapies and understanding underlying mechanisms of the condition.

Autologous fat grafting offers hope for patients with alopecia, especially those with scarring, by reducing inflammation and stimulating hair growth.

Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women's Hospital, discusses the recent FDA approval of deuruxolitinib for the treatment of moderate to severe alopecia areata.

Posters presented at the Society for Pediatric Dermatology Annual Meeting shed new light on pediatric hair loss, including the rising prevalence of androgenetic alopecia in children, the potential of artificial intelligence to assess hair loss severity, and the long-term safety of ritlecitinib for treating alopecia areata in adolescents.

Patients with alopecia areata (AA) face significant out-of-pocket costs for treatments, despite many having limited efficacy.

The FDA has approved deuruxolitinib, an oral medication developed by Sun Pharma, as the first-line treatment for adults with moderate to severe alopecia areata.